CLINICAL TRIALS PROFILE FOR DESVENLAFAXINE SUCCINATE

All Clinical Trials for Desvenlafaxine Succinate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00256685 ↗	Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2004-09-01	The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with menopause, and also to assess the effects of DVS on sleep parameters and health outcomes indicators.
NCT00283842 ↗	Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy	Terminated	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2006-03-01	The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment of neuropathic pain associated with diabetic peripheral neuropathy.
NCT00369343 ↗	Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2006-09-01	Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of major depressive disorder (MDD), for vasomotor symptoms (VMS) associated with menopause, and for pain associated with peripheral diabetic neuropathy, as well as for the treatment of fibromyalgia syndrome. This study will investigate the safety, efficacy, and tolerability of DVS SR in women with MDD who are peri- and postmenopausal.
NCT00369434 ↗	Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2006-06-01	The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS SR, an extended release form of desvenlafaxine succinate, in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) associated with menopause in a population of postmenopausal women.
NCT00384033 ↗	Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder	Completed	Pfizer	Phase 3	2006-09-01	The primary purpose of this study is to evaluate the efficacy and safety of two doses of DVS SR (50 and 100 mg/day) in the treatment of adults with Major Depressive Disorder.
NCT00397176 ↗	Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 1	2006-11-01	Safety, tolerability, and pharmacokinetics (PK) of desvenlafaxine succinate sustained release (DVS SR) in healthy Japanese female subjects.

Clinical Trial Conditions for Desvenlafaxine Succinate

Condition Name

Condition Name for Desvenlafaxine Succinate
Intervention	Trials
Major Depressive Disorder	18
Depressive Disorder, Major	5
Vasomotor Symptoms	4
Depression	3

Condition MeSH

Condition MeSH for Desvenlafaxine Succinate
Intervention	Trials
Depression	26
Depressive Disorder	26
Depressive Disorder, Major	25
Disease	15

Clinical Trial Locations for Desvenlafaxine Succinate

Trials by Country

Trials by Country for Desvenlafaxine Succinate
Location	Trials
United States	410
Canada	22
Japan	21
Mexico	6
South Africa	6

Trials by US State

Trials by US State for Desvenlafaxine Succinate
Location	Trials
Florida	22
Ohio	19
California	18
Texas	17
Georgia	15

Clinical Trial Progress for Desvenlafaxine Succinate

Clinical Trial Phase

Clinical Trial Phase for Desvenlafaxine Succinate
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	22
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Desvenlafaxine Succinate
Clinical Trial Phase	Trials
Completed	32
Terminated	4
Unknown status	3

Clinical Trial Sponsors for Desvenlafaxine Succinate

Sponsor Name

Sponsor Name for Desvenlafaxine Succinate
Sponsor	Trials
Pfizer	22
Wyeth is now a wholly owned subsidiary of Pfizer	16
McMaster University	1

Sponsor Type

Sponsor Type for Desvenlafaxine Succinate
Sponsor	Trials
Industry	39
Other	8